Human Molecular Genetics Advance Access originally published online on February 8, 2006
Human Molecular Genetics 2006 15(6):965-977; doi:10.1093/hmg/ddl013
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regional and cellular gene expression changes in human Huntington's disease brain




1Department of Psychological Medicine and 2Department of Medical Genetics, Wales College of Medicine and School of Biosciences, Cardiff University, Heath Park, Cardiff CF14 4XN, Wales, UK, 3Fred Hutchinson Cancer Research Center, Seattle, WA 98109 USA, 4Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland, 5National Center of Competence in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research (ISREC) and Swiss Institute of Bioinformatics (SIB), CH-1015 Lausanne, Switzerland, 6Department of Anatomy with Radiology, University of Auckland, Private Bag 92019, Auckland, New Zealand, 7MassGeneral Institute of Neurodegenerative Disease (MIND), Massachusetts General Hospital, Charlestown, MA 02129, USA, 8Department of Statistics, University of California, Berkeley, CA 94720-3860, USA, 9Auckland City Hospital, Auckland, New Zealand, 10Columbia University, New York, NY 10032, USA and 11Hereditary Disease Foundation, Santa Monica, CA 90405, USA
* To whom correspondence should be addressed at: Laboratory of Functional Neurogenomics AI 2138, Ecole Polytechnique Fédérale de Lausanne (EPFL), Station 15, CH-1015 Lausanne, Switzerland. Tel:+41 216939533; Fax: +41 216939628; Email: ruth.luthi-carter{at}epfl.ch
Received December 5, 2005; Accepted February 1, 2006
Huntington's disease (HD) pathology is well understood at a histological level but a comprehensive molecular analysis of the effect of the disease in the human brain has not previously been available. To elucidate the molecular phenotype of HD on a genome-wide scale, we compared mRNA profiles from 44 human HD brains with those from 36 unaffected controls using microarray analysis. Four brain regions were analyzed: caudate nucleus, cerebellum, prefrontal association cortex [Brodmann's area 9 (BA9)] and motor cortex [Brodmann's area 4 (BA4)]. The greatest number and magnitude of differentially expressed mRNAs were detected in the caudate nucleus, followed by motor cortex, then cerebellum. Thus, the molecular phenotype of HD generally parallels established neuropathology. Surprisingly, no mRNA changes were detected in prefrontal association cortex, thereby revealing subtleties of pathology not previously disclosed by histological methods. To establish that the observed changes were not simply the result of cell loss, we examined mRNA levels in laser-capture microdissected neurons from Grade 1 HD caudate compared to control. These analyses confirmed changes in expression seen in tissue homogenates; we thus conclude that mRNA changes are not attributable to cell loss alone. These data from bona fide HD brains comprise an important reference for hypotheses related to HD and other neurodegenerative diseases.
Present address: MRC Centre for Neurodegeneration Research, Department of Psychological Medicine, Box PO 70, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK.
The authors wish it to be known that, in their opinion, the last three authors should be regarded as joint Senior Authors.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
F. J. Bode, M. Stephan, H. Suhling, R. Pabst, R. H. Straub, K. A. Raber, M. Bonin, H. P. Nguyen, O. Riess, A. Bauer, et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17{beta}-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males Hum. Mol. Genet., September 1, 2008; 17(17): 2595 - 2609. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bjorkqvist, E. J. Wild, J. Thiele, A. Silvestroni, R. Andre, N. Lahiri, E. Raibon, R. V. Lee, C. L. Benn, D. Soulet, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease J. Exp. Med., August 4, 2008; 205(8): 1869 - 1877. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Chen-Plotkin, F. Geser, J. B. Plotkin, C. M. Clark, L. K. Kwong, W. Yuan, M. Grossman, V. M. Van Deerlin, J. Q. Trojanowski, and V. M.-Y. Lee Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration Hum. Mol. Genet., May 15, 2008; 17(10): 1349 - 1362. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Brochier, M.-C. Gaillard, E. Diguet, N. Caudy, C. Dossat, B. Segurens, P. Wincker, E. Roze, J. Caboche, P. Hantraye, et al. Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models Physiol Genomics, April 21, 2008; 33(2): 170 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-O. Kim, P. Chawla, R. P. Overland, E. Xia, G. Sadri-Vakili, and J.-H. J. Cha Altered Histone Monoubiquitylation Mediated by Mutant Huntingtin Induces Transcriptional Dysregulation J. Neurosci., April 9, 2008; 28(15): 3947 - 3957. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Rosas, D. H. Salat, S. Y. Lee, A. K. Zaleta, V. Pappu, B. Fischl, D. Greve, N. Hevelone, and S. M. Hersch Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity Brain, April 1, 2008; 131(4): 1057 - 1068. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, A. Grupe, C. Rowland, P. Holmans, R. Segurado, R. Abraham, L. Jones, J. Catanese, D. Ross, K. Mayo, et al. Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease Hum. Mol. Genet., March 1, 2008; 17(5): 759 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Anderson, F. Roncaroli, A. Hodges, M. Deprez, and F. E. Turkheimer Chromosomal profiles of gene expression in Huntington's disease Brain, February 1, 2008; 131(2): 381 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Strand, Z. C. Baquet, A. K. Aragaki, P. Holmans, L. Yang, C. Cleren, M. F. Beal, L. Jones, C. Kooperberg, J. M. Olson, et al. Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration J. Neurosci., October 24, 2007; 27(43): 11758 - 11768. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Runne, A. Kuhn, E. J. Wild, W. Pratyaksha, M. Kristiansen, J. D. Isaacs, E. Regulier, M. Delorenzi, S. J. Tabrizi, and R. Luthi-Carter Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood PNAS, September 4, 2007; 104(36): 14424 - 14429. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Balleine, M. R. Delgado, and O. Hikosaka The Role of the Dorsal Striatum in Reward and Decision-Making J. Neurosci., August 1, 2007; 27(31): 8161 - 8165. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kuhn, D. R. Goldstein, A. Hodges, A. D. Strand, T. Sengstag, C. Kooperberg, K. Becanovic, M. A. Pouladi, K. Sathasivam, J.-H. J. Cha, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage Hum. Mol. Genet., August 1, 2007; 16(15): 1845 - 1861. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zuccato, N. Belyaev, P. Conforti, L. Ooi, M. Tartari, E. Papadimou, M. MacDonald, E. Fossale, S. Zeitlin, N. Buckley, et al. Widespread Disruption of Repressor Element-1 Silencing Transcription Factor/Neuron-Restrictive Silencer Factor Occupancy at Its Target Genes in Huntington's Disease J. Neurosci., June 27, 2007; 27(26): 6972 - 6983. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sadri-Vakili, B. Bouzou, C. L. Benn, M.-O. Kim, P. Chawla, R. P. Overland, K. E. Glajch, E. Xia, Z. Qiu, S. M. Hersch, et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models Hum. Mol. Genet., June 1, 2007; 16(11): 1293 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zourlidou, T. Gidalevitz, M. Kristiansen, C. Landles, B. Woodman, D. J. Wells, D. S. Latchman, J. de Belleroche, S. J. Tabrizi, R. I. Morimoto, et al. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation Hum. Mol. Genet., May 1, 2007; 16(9): 1078 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tagawa, S. Marubuchi, M.-L. Qi, Y. Enokido, T. Tamura, R. Inagaki, M. Murata, I. Kanazawa, E. E. Wanker, and H. Okazawa The Induction Levels of Heat Shock Protein 70 Differentiate the Vulnerabilities to Mutant Huntingtin among Neuronal Subtypes J. Neurosci., January 24, 2007; 27(4): 868 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rockabrand, N. Slepko, A. Pantalone, V. N. Nukala, A. Kazantsev, J. L. Marsh, P. G. Sullivan, J. S. Steffan, S. L. Sensi, and L. M. Thompson The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis Hum. Mol. Genet., January 1, 2007; 16(1): 61 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Tippett, H. J. Waldvogel, S. J. Thomas, V. M. Hogg, W. v. Roon-Mom, B. J. Synek, A. M. Graybiel, and R. L. M. Faull Striosomes and mood dysfunction in Huntington's disease Brain, January 1, 2007; 130(1): 206 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Georgieva, V. Moskvina, T. Peirce, N. Norton, N. J. Bray, L. Jones, P. Holmans, S. MacGregor, S. Zammit, J. Wilkinson, et al. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia PNAS, August 15, 2006; 103(33): 12469 - 12474. [Abstract] [Full Text] [PDF] |
||||





